Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relma-cel as first-line therapy in high-risk LBCL
NCT05590221Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2023
- Primary completion
- Feb 2024
- Countries
- 1
01
Overview
A Phase 2 trial of relmacabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
relmacabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05590221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05590221.